Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International (NASDAQ: DYAI), a biotechnology company, announced its CEO, Mark Emalfarb, will present at the World Vaccine Congress in Washington, D.C. from April 4-6, 2023. Emalfarb's presentation, scheduled for April 5, will focus on transforming manufacturing and bridging technology gaps in vaccine production.

Additionally, he will provide an update on the Phase 1 Clinical Trial for the DYAI-100 COVID-19 vaccine. Key trial milestones include completing dosing in February 2023, with no serious adverse events reported and a full study report expected in the second half of 2023.

Dyadic International (NASDAQ: DYAI) has received regulatory approval for its Phase 1 trial of the DYAI-100 COVID-19 booster vaccine. The trial has successfully completed dosing for both low and high groups with no serious adverse events reported. The company reported a 21.9% year-over-year revenue increase for 2022, reaching approximately $2.93 million. Dyadic maintains cash and investments of $12.7 million, sufficient to fund operations into 2024. Significant collaborations with Janssen, Hengrui, and Phibro have been established, alongside the initiation of the Dapibus™ platform for microbial protein production. A conference call discussing financial results is scheduled for today at 5 PM ET.

Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its financial results for the year ended 2022 and host a corporate update on March 29, 2023, at 5:00 p.m. ET. The company, focused on innovative microbial platforms for protein production and biopharmaceuticals, has developed C1 and Dapibus™ technologies. These platforms aim to lower production costs and enhance the performance of vaccines and biologics. Dyadic's initiatives include advancing its COVID-19 vaccine candidate, DYAI-100, and expanding its pipeline of biologic products. Investors can tune into the live conference call via the provided webcast link.

Dyadic International has completed dosing for all participants in its Phase 1 clinical trial of the DYAI-100 COVID-19 booster vaccine candidate. No serious adverse events have been reported, indicating a favorable safety profile thus far. This trial aims to assess both the safety and antibody response from the vaccine, produced using Dyadic's innovative C1-cell protein production platform. Results are anticipated in Q2 2023, with a comprehensive study report expected in the second half of the year. The study's success could enhance interest and adoption of Dyadic's technology across various sectors, including academic and governmental organizations.

Dyadic International, a biotechnology company listed on NASDAQ under the symbol DYAI, announced participation in key investor and industry events in March 2023. Notable engagements include the 16th European Conference on Fungal Genetics and the 35th Annual Roth Conference. The company’s innovative microbial platforms aim to meet the rising demand for affordable biopharmaceuticals.

Dyadic International, a biotechnology company, announced that CEO Mark Emalfarb will participate in two investor conferences: the BIO CEO & Investor Conference on February 6, 2023, in New York, and the 35th Annual Roth Conference from March 12-14, 2023, in California. Emalfarb is available for one-on-one meetings during these events. Dyadic focuses on innovative microbial platforms for protein bioproduction and biopharmaceuticals, including its lead asset, the DYAI-100 COVID-19 vaccine candidate. The company aims to enhance access to affordable health solutions globally.

Dyadic International has initiated dosing in its Phase 1 clinical trial for the DYAI-100 COVID-19 booster vaccine candidate. This trial, conducted in South Africa, aims to evaluate the vaccine's clinical safety and antibody response in healthy volunteers aged 18-55. Following regulatory approval from SAHPRA in late 2022, the trial will consist of 15 subjects per cohort with a total randomization scheme of 4:1. Dosing is expected to complete within the first quarter of 2023, with results projected later this year. This marks the first human trial utilizing Dyadic’s C1 protein production platform, highlighting potential advancements in COVID-19 vaccine development.

Dyadic International, Inc. (NASDAQ: DYAI) announced a receipt of approximately $1.27 million from the sale of its equity interest in Alphazyme LLC. This investment came as part of a licensing agreement whereby Dyadic granted a non-exclusive license to its technology. The agreement allows Dyadic to receive milestone and royalty payments from Alphazyme's sales of C1 expressed products, plus potential additional payments based on future sales of Alphazyme's existing products. Dyadic is focused on biopharmaceutical innovations for human and animal health, leveraging its C1-cell technology and other platforms.

Dyadic International will participate in the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12, 2023, in San Francisco, CA. CEO Mark Emalfarb will present on January 8, focusing on advancements in Dyadic's C1-cell protein expression platform and its first Phase 1 clinical trial, expected to commence this month. Emalfarb will discuss the efficacy of C1-produced COVID-19 ferritin nanoparticle vaccines, supported by data from respected institutions.